265 related articles for article (PubMed ID: 34049607)
1. Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts.
Oelofse S; Esmail A; Diacon AH; Conradie F; Olayanju O; Ngubane N; Howell P; Everitt D; Crook AM; Mendel CM; Wills GH; Olugbosi M; Del Parigi A; Sun E; Calatroni A; Spigelman M; Dheda K
Int J Tuberc Lung Dis; 2021 Jun; 25(6):453-460. PubMed ID: 34049607
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.
Gomez GB; Siapka M; Conradie F; Ndjeka N; Garfin AMC; Lomtadze N; Avaliani Z; Kiria N; Malhotra S; Cook-Scalise S; Juneja S; Everitt D; Spigelman M; Vassall A
BMJ Open; 2021 Dec; 11(12):e051521. PubMed ID: 34862287
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Replacing Linezolid with OTB-658 in Anti-Tuberculosis Regimens in Murine Models.
Liu H; Zhu H; Fu L; Zhang W; Chen X; Wang B; Guo S; Ding Y; Wang N; Li D; Lu Y
Antimicrob Agents Chemother; 2023 Feb; 67(2):e0139922. PubMed ID: 36622240
[TBL] [Abstract][Full Text] [Related]
4. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925
[TBL] [Abstract][Full Text] [Related]
5. Sterile tuberculous granuloma in a patient with XDR-TB treated with bedaquiline, pretomanid and linezolid.
Howell P; Upton C; Mvuna N; Olugbosi M
BMJ Case Rep; 2021 Dec; 14(12):. PubMed ID: 34876446
[TBL] [Abstract][Full Text] [Related]
6. Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model.
Li SY; Converse PJ; Betoudji F; Lee J; Mdluli K; Upton A; Fotouhi N; Nuermberger EL
Antimicrob Agents Chemother; 2023 Apr; 67(4):e0003523. PubMed ID: 36920217
[TBL] [Abstract][Full Text] [Related]
7. Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis.
Mulder C; Rupert S; Setiawan E; Mambetova E; Edo P; Sugiharto J; Useni S; Malhotra S; Cook-Scalise S; Pambudi I; Kadyrov A; Lawanson A; van den Hof S; Gebhard A; Juneja S; Sohn H
BMJ Glob Health; 2022 Jan; 7(1):. PubMed ID: 34992077
[TBL] [Abstract][Full Text] [Related]
8. Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis.
Xu J; Li SY; Almeida DV; Tasneen R; Barnes-Boyle K; Converse PJ; Upton AM; Mdluli K; Fotouhi N; Nuermberger EL
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30833432
[TBL] [Abstract][Full Text] [Related]
9. Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States.
Haley CA; Macias P; Jasuja S; Jones BA; Rowlinson MC; Jaimon R; Onderko P; Darnall E; Gomez ME; Peloquin C; Ashkin D; Goswami ND
Emerg Infect Dis; 2021 Jan; 27(1):332-4. PubMed ID: 33227229
[TBL] [Abstract][Full Text] [Related]
10. Randomised trial to evaluate the effectiveness and safety of varying doses of linezolid with bedaquiline and pretomanid in adults with pre-extensively drug-resistant or treatment intolerant/non-responsive multidrug-resistant pulmonary tuberculosis: study protocol.
Padmapriyadarsini C; Devaleenal B; Ponnuraja C; Ramraj B; Singla R; Parmar M; Mattoo S; Mandal S
BMJ Open; 2022 Aug; 12(8):e058606. PubMed ID: 36038181
[TBL] [Abstract][Full Text] [Related]
11. Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease.
Haley CA; Schechter MC; Ashkin D; Peloquin CA; Peter Cegielski J; Andrino BB; Burgos M; Caloia LA; Chen L; Colon-Semidey A; DeSilva MB; Dhanireddy S; Dorman SE; Dworkin FF; Hammond-Epstein H; Easton AV; Gaensbauer JT; Ghassemieh B; Gomez ME; Horne D; Jasuja S; Jones BA; Kaplan LJ; Khan AE; Kracen E; Labuda S; Landers KM; Lardizabal AA; Lasley MT; Letzer DM; Lopes VK; Lubelchek RJ; Patricia Macias C; Mihalyov A; Misch EA; Murray JA; Narita M; Nilsen DM; Ninneman MJ; Ogawa L; Oladele A; Overman M; Ray SM; Ritger KA; Rowlinson MC; Sabuwala N; Schiller TM; Schwartz LE; Spitters C; Thomson DB; Tresgallo RR; Valois P; Goswami ND;
Clin Infect Dis; 2023 Oct; 77(7):1053-1062. PubMed ID: 37249079
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Dynamic Efficacy Endpoints of the Nix-TB Trial.
Solans BP; Imperial MZ; Olugbosi M; Savic RM
Clin Infect Dis; 2023 Jun; 76(11):1903-1910. PubMed ID: 36804834
[TBL] [Abstract][Full Text] [Related]
13. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
Conradie F; Bagdasaryan TR; Borisov S; Howell P; Mikiashvili L; Ngubane N; Samoilova A; Skornykova S; Tudor E; Variava E; Yablonskiy P; Everitt D; Wills GH; Sun E; Olugbosi M; Egizi E; Li M; Holsta A; Timm J; Bateson A; Crook AM; Fabiane SM; Hunt R; McHugh TD; Tweed CD; Foraida S; Mendel CM; Spigelman M;
N Engl J Med; 2022 Sep; 387(9):810-823. PubMed ID: 36053506
[TBL] [Abstract][Full Text] [Related]
14. A Modified BPaL Regimen for Tuberculosis Treatment replaces Linezolid with Inhaled Spectinamides.
Ali MZ; Dutt TS; MacNeill A; Walz A; Pearce C; Lam H; Philp J; Patterson J; Henao-Tamayo M; Lee RE; Liu J; Robertson GT; Hickey AJ; Meibohm B; Gonzalez-Juarrero M
bioRxiv; 2024 Jun; ():. PubMed ID: 38014249
[TBL] [Abstract][Full Text] [Related]
15. Favourable outcomes in RR-TB patients using BPaL and other WHO-recommended second-line anti-TB drugs.
Rikhotso MC; Ledwaba SE; Ngandu JK; Mavumengwana V; Kinnear CJ; Warren R; Potgieter N; Traoré AN
Int J Tuberc Lung Dis; 2023 Aug; 27(8):599-605. PubMed ID: 37491748
[TBL] [Abstract][Full Text] [Related]
16. Bedaquiline and Linezolid improve anti-TB treatment outcome in drug-resistant TB patients with HIV: A systematic review and meta-analysis.
Wu Y; Zhang Y; Wang Y; Wei J; Wang W; Duan W; Tian Y; Ren M; Li Z; Wang W; Zhang T; Wu H; Huang X
Pharmacol Res; 2022 Aug; 182():106336. PubMed ID: 35779814
[TBL] [Abstract][Full Text] [Related]
17. Model-based dose optimization framework for bedaquiline, pretomanid and linezolid for the treatment of drug-resistant tuberculosis.
Mehta K; Guo T; van der Graaf PH; van Hasselt JGC
Br J Clin Pharmacol; 2024 Feb; 90(2):463-474. PubMed ID: 37817504
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
[TBL] [Abstract][Full Text] [Related]
19. Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant
Almeida D; Converse PJ; Li SY; Upton AM; Fotouhi N; Nuermberger EL
Antimicrob Agents Chemother; 2021 Nov; 65(12):e0141221. PubMed ID: 34570644
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis.
Li H; Salinger DH; Everitt D; Li M; Del Parigi A; Mendel C; Nedelman JR
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
